Sartorius Buys a CRO
This is Sartorius Stedim’s first acquisition of a CRO. BioOutsource’s services are used in early-phase drug characterization and comparability, and for lot release testing. The acquisition will enable geographical expansion of the business and growth in the biosimilars market.
Shimadzu Names New CEO
Aubagne, France 4/17/15; Glasgow, UK 4/17/15—Biopharmaceutical industry provider Sartorius Stedim Biotech has acquired BioOutsource for an undisclosed amount. BioOutsource provides contract testing services for monitoring the safety and quality of biologic drugs and vaccines, specializing in services for biosimilars. Based in Glasgow, Scotland, BioOutsource’s 12-month revenues totaled around €9 million ($12 million = €0.75 = $1). The company has 85 employees. “By adding contract testing services, we will be able to support our biopharma clients even better in their drive to fast-track their new drug candidates through the development and clinical-test phases and facilitate lot release testing in large-scale manufacturing,” commented Reinhard Vogt, member of Sartorius Stedim’s Board.
